BPD Research
Long/short equity

Upcoming Catalysts Could Push ChemoCentryx To Double In 2013

Company Overview

Founded in 1997, ChemoCentryx (NASDAQ:CCXI) only recently went public in February 2012. The company currently has a pipeline of six small molecule drugs (three of which are partnered with GSK) that target specific chemokine receptors. Chemo-attractant cytokines, or chemokines, are chemical messengers involved in coordinating the body's inflammatory response to infection, irritation, or injury. Different combinations of chemokines and their respective receptors can direct different inflammatory responses. Chronic inflammation over a long period of time can lead to certain auto-immune diseases, including inflammatory bowel disease ("IBD"), rheumatoid arthritis ("RA"), diabetic nephropathy, multiple sclerosis, and others.

Supported by 490 issued or allowed patents (with expirations ranging from 2020 to 2029) and 225 patents pending, CCXI's pipeline...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details